Additional file 2 of Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

Additional file 2: Supplementary Table 2. (2nd Sensitivity analysis). Demographic and clinical characteristics of patients with inflammatory arthritis who discontinued therapy according to clinical remission vs patients who continue. Footnote to table 1. Data are shown as mean (SD), except for categorical variables, which are shown as total number (percentage); Disc: Discontinuation; Rem: Remission; MTX: methotrexate, LFN: leflunomide; SSZ: sulfasalazine; i: inhibitor; RF: rheumatoid factor; ACPA: anti–citrullinated peptide antibody. *Moderate-high disease activity was defined as DAS28 ≥3.2 or BASDAI ≥4, depending on the disease.